The subsequent advance in anti-obesity treatment was the development of dual incretins, such as tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist, and cotadutide, a dual GLP-1 and glucagon agonist. Here, GLP1R is linked to Obesity.